Cargando…

Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages

AIM: To evaluate the cost-effectiveness of therapeutic strategies initiated at different stages of liver fibrosis using three direct-acting antivirals (DAAs), sofosbuvir-ledipasvir (SL), glecaprevir-pibrentasvir (GP), and elbasvir plus grazoprevir (E/G), for Japanese patients with chronic hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suenaga, Riichiro, Suka, Machi, Hirao, Tomohiro, Hidaka, Isao, Sakaida, Isao, Ishida, Haku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016275/ https://www.ncbi.nlm.nih.gov/pubmed/33793594 http://dx.doi.org/10.1371/journal.pone.0248748

Ejemplares similares

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
por: Izhari, Mohammad Asrar
Publicado: (2023)

Iron-rich Kupffer cells exhibit phenotypic changes during the development of liver fibrosis in NASH
por: Kanamori, Yohei, et al.
Publicado: (2021)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
por: Grottenthaler, Julia M., et al.
Publicado: (2018)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

Epidemiological approach to nosocomial infection surveillance data: the Japanese Nosocomial Infection Surveillance System
por: Suka, Machi, et al.
Publicado: (2007)

Help-Seeking Behavior and Psychological Distress by Age in a Nationally Representative Sample of Japanese Employees
por: Yamauchi, Takashi, et al.
Publicado: (2020)

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
por: Frisk, P., et al.
Publicado: (2018)

Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis
por: Shakeri, Ahmad, et al.
Publicado: (2021)

Novel Therapeutic Strategy Using Interventional Radiology (IVR) for Hepatitis C Virus (HCV)-Related Decompensated Liver Cirrhosis: A Case Report
por: Iwamoto, Takuya, et al.
Publicado: (2019)

Perceived effectiveness rating scales applied to insomnia help-seeking messages for middle-aged Japanese people: a validity and reliability study
por: Suka, Machi, et al.
Publicado: (2017)

Changes in health status, workload, and lifestyle after starting the COVID-19 pandemic: a web-based survey of Japanese men and women
por: Suka, Machi, et al.
Publicado: (2021)

Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
por: Welzel, Tania M., et al.
Publicado: (2019)

P1096: TREATMENT OF HEPATITIS C-ASSOCIATED MARGINAL ZONE LYMPHOMA(HCV+LMZ) WITH DIRECT-ACTING ANTIVIRAL DRUGS (DAAS)
por: Lepkov, Sergey, et al.
Publicado: (2023)

Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)

Comparing responses to differently framed and formatted persuasive messages to encourage help-seeking for depression in Japanese adults: a cross-sectional study with 2-month follow-up
por: Suka, Machi, et al.
Publicado: (2018)

Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt
por: Shoun, Aly Atef, et al.
Publicado: (2022)

ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs)
por: Ghanem, Samar, et al.
Publicado: (2023)

Impact of postprandial hyperglycemia at clinic visits on the incidence of cardiovascular events and all‐cause mortality in patients with type 2 diabetes
por: Takao, Toshiko, et al.
Publicado: (2017)

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
por: Chen, Zhi-wei, et al.
Publicado: (2016)

Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series
por: Ambarsari, Cahyani Gita, et al.
Publicado: (2020)

292. No association Between Direct-acting Antiviral (DAA) Therapy and Varicella-Zoster Virus (VSV) Reactivation in an Analysis of 37 Prospective Clinical Trials
por: Rohde, Maximilian, et al.
Publicado: (2019)

Role of Inflammatory/Immune Response and Cytokine Polymorphisms in the Severity of Chronic Hepatitis C (CHC) before and after Direct Acting Antiviral (DAAs) Treatment
por: Ferreira, Joana, et al.
Publicado: (2023)

Risk Factors of Low APGAR Score in Japanese Full-term Deliveries: A Case-control Study
por: Suka, Machi, et al.
Publicado: (2007)

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

Efficacy of Contrast-enhanced Harmonic Endoscopic Ultrasonography in the Diagnosis of Pancreatic Ductal Carcinoma
por: Uekitani, Toshiyuki, et al.
Publicado: (2016)

Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
por: Aebi-Popp, Karoline, et al.
Publicado: (2016)

Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study
por: Pereira, Gustavo H., et al.
Publicado: (2022)

Combined effect of diabetic retinopathy and diabetic kidney disease on all‐cause, cancer, vascular and non‐cancer non‐vascular mortality in patients with type 2 diabetes: A real‐world longitudinal study
por: Takao, Toshiko, et al.
Publicado: (2020)

EUS-guided antegrade metallic stent placement using the stent-in-stent method with a 6-Fr novel slim delivery system in a patient with malignant hilar biliary obstruction
por: Suenaga, Shigeyuki, et al.
Publicado: (2021)

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification
por: Ishikawa, Tsuyoshi, et al.
Publicado: (2019)

Short-term Effects of Hepatic Arterial Buffer Responses Induced by Partial Splenic Embolization on the Hepatic Function of Patients with Cirrhosis According to the Child-Pugh Classification
por: Ishikawa, Tsuyoshi, et al.
Publicado: (2020)

Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
por: Brothers, Sarah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lmc2bqpmnue1nlo4v0ir4k67mt